IVD Antibody Development Services for sCD40L Marker

Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the sCD40L marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.

CD40 ligand (CD40L), a member of the tumor necrosis factor family, is involved in the pathogenesis of atherosclerosis through its prothrombotic and inflammatory characteristics. CD40L is generated in hematopoietic cell types, including T lymphocytes, platelets and monocytes, or nonhematopoietic cells, for example, endothelial and smooth muscle cells. CD40L serves essential roles in endothelial cell activation, the secretion of inflammatory cytokines, the modulation of apoptosis and angiogenesis. Recently, the soluble form of the CD40L, soluble CD40L (sCD40L), has got much attention due to its clinical validity as a marker of cardiovascular events. Meanwhile, a growth of sCD40L in the blood was discovered in a number of autoimmune disorders, as well as in chronic inflammatory diseases. Remarkably, sCD40L is connected with unstable plaque and may be a crucial predictor of plaque instability and plaque complication.

Figure 1. The left graph shows three functions of sCD40L that secreted from platelets during thrombosis. The right graph shows the shedding of soluble sCD40L during platelet stimulation. (André, P. 2002)

sCD40L Marker of Myocardial Infarction

MI is able to be identified by clinical features, such as electrocardiographic (ECG) findings, and increased values of biomarkers of myocardial necrosis. It is a main cause of death and disability all over the world. Besides, MI may be the premier performance of coronary artery disease (CAD) or it may occur repeatedly in patients with established disease. A study demonstrated that plasma levels of sCD40L were superior predictors of cardiovascular events, comprising MI and ischemic stroke in patients with AF. Due to the prothrombotic property of sCD40L, it is more helpful than other biomarkers such as p-selection in predicting cardiovascular events. It has also been indicated that time change of sCD40L over 1 month after MI onset was correlated with G894T eNOS polymorphism and VEGF concentrations. These results suggested that the sCD40L cannot be regarded just as being related to thrombosis and inflammation, but also as playing a relevant role in vascular and endothelial dysfunction.

Figure 2. Sketch map of CD40/CD40L and inflammation. When sCD40L engages CD40 on ECs, signaling induces production of ROS, which prevent NO synthesis, and improve endothelial dysfunction. Plaque thrombogenicity is improved by CD40/CD40L–mediated TF expression,, which in turn activates platelets. The activated platelets produce more sCD40L, enhancing the inflammatory reaction. (Szmitko, P. E. 2003)

sCD40L Marker of Diabetes

Diabetes is a severe complex situation that influences the whole body. The blood glucose or blood sugar levels are too high in patients with diabetes. Diabetes may also lead to heart disease, stroke and even the need to remove a limb. There are several different types of diabetes, among which, type 1, type 2 and gestational diabetes are three major types. Research has proven that raised intracellular levels in and release of sCD40L by platelets of diabetic subjects is a new mechanism which enables to explain stepped-up atherogenesis in diabetes. Meanwhile, the induction of sCD40L expression and secretion from platelets by glucose and AGEs also add evidence to that.

IVD Antibody Development Services Targeting sCD40L Marker

Based on the rapid development of IVD technology and novel biomarkers, IVD antibodies are extensively used for disease screening and therapeutic monitoring. Diverse immunoassays are applied, including lateral flow assay, immunochemistry, sandwich ELISA, etc. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to deliver high-quality IVD antibody development services targeting numerous biomarkers, such as sCD40L. With years of devotion and accumulation in this particular field, Creative Biolabs is confident in offering you the best products and services.

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. André, P. (2002). “Platelet-derived CD40L the switch-hitting player of cardiovascular disease.” Circulation 106(8), 896-899.
2. Szmitko, P. E. (2003). “New markers of inflammation and endothelial cell activation part I.” Circulation 108(16), 1917-1923.

For Research Use Only.